title: The effect of imatinib mesylate on the contractility of isolated rabbit myometrial strips.
abstract: BACKGROUND
  C-kit receptor expressing interstitial cells generate and coordinate the electrical signals that control peristalsis in the gut. However, the function of interstitial cells in the myometrium is not known.
  
  
  METHODS
  (1) Sections of rabbit myometrium were subjected to immunohistochemical staining for the c-kit receptor. (2) Spontaneously contracting myometrial strips from New Zealand White rabbits near term were mounted in an organ bath and attached to a tension-recording device. The effect of increased concentrations of the c-kit receptor antagonist imatinib mesylate on these contractions was observed. The main outcome measures were the change in frequency, amplitude and duration of contraction.
  
  
  RESULTS
  (1) Multipolar cells expressing c-kit were identified in the fibromuscular septum confirming the presence of interstitial cells in rabbit myometrium. (2) Imatinib decreased the amplitude of contractions by approximately 20% at 100 microM. No effect was seen at lower concentrations. No effect of imatinib on frequency or duration of contractions was observed at any of the concentrations studied.
  
  
  CONCLUSIONS
  In isolated rabbit myometrium, acute inhibition of the c-kit receptor by imatinib mesylate affects only the amplitude of spontaneous contractions at concentrations, the equivalent of x10-100 the normal therapeutic concentration.
authors.affiliation: Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium. livvygraham@yahoo.co.uk
authors.forename: G
authors.initials: G
authors.lastname: Hutchings
authors.forename: J
authors.initials: J
authors.lastname: Deprest
authors.forename: B
authors.initials: B
authors.lastname: Nilius
authors.forename: T
authors.initials: T
authors.lastname: Roskams
authors.forename: D
authors.initials: D
authors.lastname: De Ridder
mesh_terms: D000818:Animals; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D009215:Myometrium / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011247:Pregnancy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000494:pharmacology*; D011817:Rabbits; D011897:Random Allocation; D046509:Tissue Culture Techniques; D014590:Uterine Contraction / Q000187:drug effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit